ledisa glp 1 More people with type diabetes are using GLP-1 drugs, study finds, despite limited evidence on safety or effectiveness SGLT2i and GLP-1 RA therapy

Converting injection doses to nasal spray The bioavailability problem: Injection bioavailability : ~80-100% (nearly all absorbed) Nasal bioavailability: ~30% (only 30% absorbed) Ratio: Need 2.5-3x higher nasal dose Individual variation significant Conversion formula: Injection dose 2.5 to 3 = Nasal dose Example: 1.5mg injection 3.75-4.5mg nasal Round to practical spray amounts Start conservative, adjust up Typical conversions: Starting recommendations: Men: Start 4mg nasal (4 sprays of 10mg/ml) Women: Start 2.5-3mg nasal (2.5-3 sprays) First time: Start lower end Assess tolerance and response Increase by 0.5-1mg if needed Why conversion isn't perfect: Individual absorption varies Nasal technique matters Nasal congestion affects absorption Time of day may influence Experimentation required Dose escalation strategy First-time nasal spray protocol: Trial 1: Conservative start Men: 3mg (3 sprays) Women: 2mg (2 sprays) Goal: Assess tolerance, sides Expect possibly weak effects Focus on side effect profile Trial 2: Standard dose Men: 4mg (4 sprays) Women: 3mg (3 sprays) Should produce noticeable effects If weak, prepare to increase Track nausea level Trial 3: Increase if needed Men: 5mg (5 sprays) Women: 4mg (4 sprays) Only if Trial 2 insufficient Check for nausea increase Most find sweet spot here Trial 4+: Fine tuning Adjust by 0.5-1mg increments Find minimum effective dose Balance efficacy vs sides Maximum: Men 6mg, Women 5mg Don't exceed without reason Dose response tracking: When to stop increasing: Desired effects achieved Nausea becomes intolerable Reached maximum safe dose Diminishing returns Individual ceiling See peptide dosing guide for general principles

The results showed that garlic essential oil significantly attenuated the reduction of testicular SOD, CAT, and glutathione peroxidase (GPx) activities induced by CYP

GLP-1s Continue to Gain Ground Initially approved for diabetes, GLP-1s have gained national attention for their effectiveness in treating obesity and continue to expand their clinical reach rapidly

Studies have shown that children with constipation have a lower fiber intake than other children